- Home
- TLPH vs CSCI Comparison
TLPH vs CSCI Comparison
Compare TLPH & CSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- CSCI
- Stock Information
- Founded
- TLPH 2005
- CSCI 1990
- Country
- TLPH United States
- CSCI Canada
- Employees
- TLPH N/A
- CSCI N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- CSCI
- Sector
- TLPH Health Care
- CSCI
- Exchange
- TLPH Nasdaq
- CSCI NYSE
- Market Cap
- TLPH 10.6M
- CSCI 10.6M
- IPO Year
- TLPH 2011
- CSCI 1996
- Fundamental
- Price
- TLPH $0.46
- CSCI $3.44
- Analyst Decision
- TLPH Strong Buy
- CSCI
- Analyst Count
- TLPH 1
- CSCI 0
- Target Price
- TLPH $6.00
- CSCI N/A
- AVG Volume (30 Days)
- TLPH 42.9K
- CSCI 1.9K
- Earning Date
- TLPH 08-13-2025
- CSCI 08-12-2025
- Dividend Yield
- TLPH N/A
- CSCI N/A
- EPS Growth
- TLPH N/A
- CSCI N/A
- EPS
- TLPH N/A
- CSCI N/A
- Revenue
- TLPH $27,000.00
- CSCI $9,030,000.00
- Revenue This Year
- TLPH N/A
- CSCI N/A
- Revenue Next Year
- TLPH $14,533.26
- CSCI N/A
- P/E Ratio
- TLPH N/A
- CSCI N/A
- Revenue Growth
- TLPH N/A
- CSCI 36.51
- 52 Week Low
- TLPH $0.43
- CSCI $1.96
- 52 Week High
- TLPH $1.19
- CSCI $7.54
- Technical
- Relative Strength Index (RSI)
- TLPH 46.34
- CSCI N/A
- Support Level
- TLPH $0.45
- CSCI N/A
- Resistance Level
- TLPH $0.52
- CSCI N/A
- Average True Range (ATR)
- TLPH 0.03
- CSCI 0.00
- MACD
- TLPH 0.00
- CSCI 0.00
- Stochastic Oscillator
- TLPH 36.67
- CSCI 0.00
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.